International Committee │ ABA Section of Antitrust Law October 2012 │ Vol. 3 Wait Three Years and Then Two Come at Once: European Commission Moves Against Pharma Patent Settlements Matthew Hall McGuireWoods, Brussels I n July 2012, three years after it published its final re- So far as concerns the decline of novel medicines port into competition in the pharmaceutical sec
Advantag of ingestion administration way is its easiness even when applied at home. But with their help necessary treatment concentration in blood cannot be always quickly achieve amoxil online transaction is carried out on anonymity and mutual profit principles, and in addition customers will be positively surprised with quality and speed of service.
Inhibitors of protein synthesisAntibacterial Agents II
Katzung, B.G. Basic and Clinical Pharmacology, Eighth Edition, Chapters 44 and 45, p774-783.
Cast of characters
Aminoglycosides (streptomycin, amikacin, tobramycin, neomycin, etc.),
Tetracycline (and minocycline, doxycycline, etc.)
Erythromycin (and azithromycin)
All of the agents discussed in this lecture are inhibitors of bacterial protein synthesis.
Given that the penicillins and cephalosporins are the antibacterial agents with the highest
therapeutic index, they are the drugs of first choice all other things being equal. The rationale for
the use of the agents discussed in this lecture are summarized below. All have a lower
therapeutic index compared to the penicillins.
To potentiate the action of penicillins in serious infections (aminoglycosides) CNS infections - (penicillins are weak acids) TB (streptomycin) - slow growing bacteria are resistant to penicillins Selectivity
Inhibition of protein synthesis catalyzed by chloramphenicol clindamycin erythromycin linezolid (fusidic
The target for all these drugs is the polysomes (polyribosomes) in the bacterial cytoplasm.
Depending on the drug, these may or may not be degraded.
Although it might be predicted that the agents above are reasonably selective (i.e., bacterial
versus human), mitochondrial protein synthesis is inhibited by the 70 S specific agents in vitro.
[Fusidic acid has not been approved for use in the USA. Derivatives of it should become
available in the near future.]
Mechanism of action
Aminoglycosides bind to the 30S subunit and block initiation of protein synthesis by forming aberrant initiation complexes. In addition, they cause miscoding at the aminoacyl-tRNA-mRNA step. Chloramphenicol and clindamycin inhibit peptidyl transferase (Note that in your textbook Tetracycline inhibits binding of aminoacyl-tRNAs at the A site. Erythromycin and spectinomycin inhibit translocation. Fusidic acid action results in the formation of a ternary complex in which the drug is bound to the ribosome together with elongation factor G in its ADP-bound state although movement of the tRNA-peptide occurs from the A to the P site. Linezolid binds to 23S RNA of the 50S ribosomal subunit.
Resistance to these agents can occur at several levels.
Resistance can occur by inability to bind to ribosomal proteins and/or RNA.
Some are also inactivated by secreted enzymes, e.g., chloramphenicol acetyl transferase,
adenylylating (and other) enzymes active against many aminoglycosides.
Tetracycline resistance can also occur by pumping the drug out of the cell faster than it gets in.
Side effects (Specific)
Aminoglycosides- nephrotoxicity, ototoxicity
Chloramphenicol- aplastic anemia
Clindamycin- pseudomembranous colitis (Clostridium difficile)
Tetracyclines-chelating agents which are deposited in bones and teeth;
Azithromycin-fewer drug interactions than erythromycin because it doesn't inhibit cytochrome
On the figure describing protein synthesis, indicate where the various classes of agents The following table of information is the basis for the next set of questions. Inhibits a specific initiation step of protein synthesis
ก F 3 (Applied Pharmacotherapeutics I I) 3620 F 132 Email address: [email protected] Integration of epidemiology, pathophysiology, clinical signs and symptoms, and principles of diagnosis and treatment of advanced cardiovascular disorders, disorders of skeletal, bone and joint systems, complicated infectious diseases including dengue fever, acid-base disorders, renal replacement therapy,